Compare Global X Lithium & Battery Tech ETF (LIT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Lithium & Battery Tech ETF vs BIO-TECHNE Corp — how do they compare? Global X Lithium & Battery Tech ETF trades at $69.77 (market cap $1.45B), while BIO-TECHNE Corp trades at $72.5 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 7.8× Global X Lithium & Battery Tech ETF's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Global X Lithium & Battery Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Lithium & Battery Tech ETF for 56 Days and BIO-TECHNE Corp for 64 Days on average.
| LIT | TECH | |
|---|---|---|
Market Cap | $1.45B | $11.36B |
Volume | 89,392 | 5,390,331 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $91.62 | $72.61 |
52-Week Low | $53.92 | $43.31 |
Typical Hold Time | 56 Days | 64 Days |
Enterprise Value | — | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIT (Global X Lithium & Battery Tech ETF) trades at $69.51, down 2.2% with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. Recent news highlights significant short interest decline (53.1% drop in September 2026) and positive catalysts from EV adoption trends. The ETF's performance reflects ongoing volatility in lithium markets amid shifting commodity prices and global electrification policies.
Outlook remains driven by long-term EV growth, though near-term risks include lithium price volatility and geopolitical tensions. Investment opportunity lies in exposure to battery technology leaders, balanced by sector-specific supply chain and regulatory uncertainties that could impact shareholder returns.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
